Press Releases

Date Title and Summary  
Toggle Summary Geron Announces Expansion of Leadership Team with Appointment of Chief Medical Officer
Aleksandra Rizo , M.D., Ph.D., former clinical lead for the imetelstat program at Janssen, joins Geron as Chief Medical Officer Additional office to be opened in New Jersey to support expansion of clinical development team Preliminary operating expense guidance for 2019 provided MENLO PARK, Calif.
Toggle Summary Geron Announces Two Presentations on Imetelstat at Upcoming European Hematology Association Annual Congress
MENLO PARK, Calif. , May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts containing clinical data and analyses related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted for presentation at the 24th European
Toggle Summary Geron Appoints Two New Independent Board Members
MENLO PARK, Calif. , March 28, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Dawn C. Bir and Elizabeth G. O’Farrell as independent members of its Board of Directors. In addition, Ms. Bir will serve as a member of the Board’s Nominating and Corporate
Toggle Summary Geron Appoints Vice President, Human Resources
MENLO PARK, Calif. , June 20, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other recently recruited senior leadership to further strengthen the organization as it expands its operations
Toggle Summary Geron Appoints Vice President, Pharmacovigilance and Drug Safety
MENLO PARK, Calif. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the hiring of the first of several key leadership positions as it rebuilds the in-house development team to support its plans to initiate a Phase 3 clinical trial of imetelstat in lower risk
Toggle Summary Geron Continues to Build Senior Leadership of Its Development Team
MENLO PARK, Calif. , May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it is continuing to build the senior leadership of its development team with the addition of a Vice President, Biometrics, and a Vice President, Manufacturing.
Toggle Summary Geron Corporation Reports First Quarter 2019 Financial Results
MENLO PARK, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2019 . As of the quarter-end, the Company had approximately $170 million in cash and marketable securities, which is sufficient to support
Toggle Summary Geron Corporation Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Events
Conference Call Scheduled for 4:30 p.m. ET today MENLO PARK, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and full year ended December 31, 2018 and recent events. As of year-end 2018, the Company had
Toggle Summary Geron Enhances Oncology Expertise to Advance Corporate Objectives
MENLO PARK, Calif. , July 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointments of Sharon McBain as Vice President, Global Regulatory Affairs and Lynn Bodarky as Vice President, Business Development. These appointments further enhance the Company’s oncology
Toggle Summary Geron Expands Senior Leadership of Its Development Team
MENLO PARK, Calif. , April 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced an expansion of its development team’s senior leadership with the addition of three highly experienced professionals for key functional areas. Their oncology and drug development expertise will